Atezolizumab with R-GEMOX in patients with transformed DLBCL

Exploring the use of atezolizumab in combination with R-CHOP in DLBCLПодробнее

Atezolizumab + obinutuzumab + venetoclax in patients with R/R DLBCLПодробнее

Atezolizumab plus R-CHOP in DLBCL: encouraging resultsПодробнее

DLBCL Prognosis & Management in Front-line Settings #oncology #lungcancer #cancer #2023Подробнее

LYSA: atezolizumab, obinutuzumab and venetoclax in R/R DLBCLПодробнее

LOTIS-5: loncastuximab tesirine + rituximab for elderly patients with R/R DLBCLПодробнее

SUNMO: mosunetuzumab + polatuzumab vedotin vs R-GemOx in R/R aggressive NHLПодробнее

Real-world outcomes of patients with transformed R/R DLBCL treated with CD19 CAR-T therapyПодробнее

SUNMO trial design: mosunetuzumab plus polatuzumab vedotin vs R-GemOx in R/R NHLПодробнее

Treatment approaches for patients with R/R DLBCL: UK perspectiveПодробнее

Updates on tafasitamab for the treatment of DLBCLПодробнее

Follicular Lymphoma Disease Transformation and Secondary Cancer RiskПодробнее

How Is Relapsed or Transformed Follicular Lymphoma Treated?Подробнее

The addition of nivolumab to R-GemOx followed by nivolumab maintenance shows a trend towards bet...Подробнее

Phase Ib/IIa study of AZD4573 + acalabrutinib in R/R DLBCLПодробнее

The STARGLO trial: glofitamab in combination with gemcitabine and oxaliplatin in R/R DLBCLПодробнее

R-GemOx plus nivolumab versus R-GemOx as second-line therapy for LBCLПодробнее

The current and future role of bispecifics in R/R DLBCL: epcoritamab, glofitamab & moreПодробнее

What is the rationale behind the combination of glofitamab + polatuzumab in patients with R/R DLBCL?Подробнее